english.prescrire.org > Spotlight > 100 most recent > Voxelotor (Oxbryta°) in sickle-cell disease

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Voxelotor (Oxbryta°) in sickle-cell disease

 Marketing Authorisations   Voxelotor binds to haemoglobin and increases its affinity for oxygen. It is claimed that this prevents sickling and premature destruction of red blood cells. A reduction in oxygen release by haemoglobin would be expected in its presence. Voxelotor has been authorised in the European Union for the treatment of haemolytic anaemia due to sickle-cell disease, as monotherapy or in combination with hydroxycarbamide. In this situation, does voxelotor correct the clinical effects of anaemia or reduce the the incidence of complications of sickle-cell disease?
Full article available for download by subscribers

©Prescrire 1 March 2024

Source: "Voxelotor (Oxbryta°) in sickle-cell disease" Prescrire Int 2024; 33 (257): 61-63. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter

Subscribe now

See also:

"Crizanlizumab (Adakveo°)
to prevent vaso-occlusive
crises in sickle-cell disease.
No proven clinical advantages,
either as an adjunct to
or instead of hydroxycarbamide"
Prescrire Int 2022;